Celularity Incorporated
17 clinical trials · Sponsor
◉ Watch Celularity Incorporated
| Record | Firm | Date |
|---|---|---|
| CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma (NCT05207722) | Celularity Incorporated | 2022-04-14 |
| CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type (NCT05218408) | Celularity Incorporated | 2021-09-01 |
| Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM (NCT04489420) | Celularity Incorporated | 2020-10-01 |
| Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 (NCT04365101) | Celularity Incorporated | 2020-09-02 |
| Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma (NCT04309084) | Celularity Incorporated | 2020-05-12 |
| Natural Killer Cell (CYNK-001) Infusions in Adults with AML (NCT04310592) | Celularity Incorporated | 2020-03-12 |
Track Celularity Incorporated automatically
Every clearance here is in the API, with alerts when new ones post.